The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-07-31

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many families of children with medically refractory epilepsy are choosing to use medicinal cannabinoids (MCBD) as an adjunctive alternative treatment option. The safety, tolerability and efficacy of these products are not known. The primary objective of this study is to determine how the use of MCBD affects children with medically refractory epilepsy in an observational study. Measures of evaluation to be used will include: laboratory values, developmental measures, seizure diaries and serial electroencephalographic (EEG) recordings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cannabis Extract in Refractory Epilepsy Study

NCT03808935

Drug Resistant Epilepsy

TERMINATED PHASE3

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

NCT02318602

Seizures

COMPLETED PHASE3

Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use)

NCT03676049

Drug Resistant Epilepsy

AVAILABLE

A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy

NCT02783092

Epilepsy

UNKNOWN PHASE3

Expanded Use of Cannabidiol Oral Solution

NCT03196934

Refractory Epilepsy

NO_LONGER_AVAILABLE

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational study of a family's choice to use MCBD and the effect of this substance on medically refractory epilepsy in children. The risks associated with this use are not well known. There have recently been reports of stroke, liver dysfunction and altered anticonvulsant levels. In addition, there have been long term risks reported of decreased memory function, cognitive problems and executive function abnormalities. This study does not condone or advocate the use of the substance but merely seeks to document the short term effects of the use in this population. It should be noted that providers at Children's Hospital Colorado are not registered providers for medicinal cannabis; therefore, this will be an observational study of effects of this substance as prescribed by other physicians outside of our institution.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy, Unspecified, Refractory (Medically)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects with medically refractory epilepsy

Pediatric epilepsy patients who are followed at Children's Hospital Colorado with medically refractory epilepsy, and whom the family has decided to treat with medical cannabis.

Medical Cannabis

Intervention Type DRUG

Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medical Cannabis

Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

medicinal cannabinoids (MCBD)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or Female \>1 month of age
2. Documentation of a diagnosis of medically refractory epilepsy as evidenced by medical records, genetic testing and/or the following clinical features:

* Failure to control seizures despite an appropriate trial of two anticonvulsant medications at therapeutic doses
3. Baseline seizure frequency of at least 2 per week of the any of the following types:

* Generalized tonic-clonic
* Clonic
* Tonic
* Hemiconvulsive
* Drop attacks
* Focal motor
* Epileptic spasms
4. 1-3 baseline anti-seizure medications at stable doses for a minimum of 4 weeks prior to enrollment.
5. Written informed consent obtained from the patient or the patient's legal representative.

Exclusion Criteria

1. Epilepsies associated with rapidly progressing neurodegenerative diseases ex: Rasmussen encephalitis, and tumors.
2. Epilepsies associated with treatable inborn errors of metabolism
3. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
4. Non-epileptic events.
5. Current use of MCBD products (Note: Patient is eligible if currently using MCBD but will be switching to a different product).

Minimum Eligible Age

1 Month

Maximum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No